ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

ASN / Education & Meetings / Kidney Week /

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: SA-PO557

The Association Between Vitamin D Level and Microvascular Complications in Persons with Type 2 Diabetes

Session Information

Category: Diabetic Kidney Disease

  • 602 Diabetic Kidney Disease: Clinical

Authors

  • Tougaard, Ninna Hahn, Steno Diabetes Center Copenhagen, Gentofte, Denmark
  • Hansen, Tine, Steno Diabetes Center Copenhagen, Gentofte, Denmark
  • Rossing, Peter, Steno Diabetes Center Copenhagen, Gentofte, Denmark
Background

The objective of this study is to examine the association between vitamin D level and presence of microvascular complications in persons with type 2 diabetes.

Methods

Cross-sectional study including 789 persons with type 2 diabetes followed at Steno Diabetes Center Copenhagen with information on plasma concentration of vitamin D and relevant clinical data. Peripheral neuropathy was defined as bilaterally decreased sensibility of vibration and minimum one symptom.

Results

The cohort included 378 persons with normoalbuminuria (NA) (mean (SD) age 63.7 (11.5) years), 260 with moderately increased albuminuria (MA) (mean age 68.3 (10.9) years) and 148 with severely increased albuminuria (SA) (mean age 67.2 (11.0) years). The overall prevalence of vitamin D deficiency (25-49 nmol/L) and severe deficiency (<25 nmol/L) was 19.3% and 6.6%, respectively. In persons with NA, MA and SA, the mean (SD) of vitamin D level was 78.1 (35.7), 75.7 (33.6) and 65.2 (35.0) nmol/L, respectively. There was no difference between the NA and MA group (p=0.41), but the difference between the NA and SA group was significant both unadjusted (p=0.0002) and after adjustment for age, sex, seasonal variation, HbA1c, smoking, BMI, systolic BP and eGFR (p=0.005). In linear regression analysis, vitamin D level was negatively associated with albuminuria unadjusted and after adjustment (both p<0.0001). When stratified into CKD stage 1 to 5; including 254, 309, 195, 20 and 11 persons, respectively, the mean (SD) vitamin D level was 70.3 (34.5), 78.6 (33.9), 74.2 (36.7), 81.5 (43.7) and 67.4 (25.9) nmol/L in stage 1 to 5. There was no difference between groups (p=0.25). The mean (SD) vitamin D level was 81.4 (41.2) nmol/L in persons with proliferative retinopathy (n=48) and 75.3 (35.0) nmol/L in persons without (n=621) (p=0.25). In persons with peripheral neuropathy (n=153), the mean (SD) vitamin D level was 74.3 (34.4) nmol/L, and 74.7 (35.4) nmol/L in persons without (n=470) (p=0.91).

Conclusion

Among persons with type 2 diabetes, persons with severely increased albuminuria had a lower vitamin D level; moreover, an inverse relationship between vitamin D level and albuminuria was demonstrated. Interestingly, no association between vitamin D level and CKD stage, proliferative retinopathy or peripheral neuropathy was observed.